multiple myeloma

Treating frail elderly patients with multiple myeloma requires different approachTransplant eligibility issues and drug regimen options raise difficult questions when treating older multiple myeloma patients.
Ten ways multiple myeloma treatment is changingAs multiple myeloma treatment improvements continue, it’s important for managed care executives to get out in front of these 10 changes on the horizon.
FDA warns about deaths in cancer drug trials
FDA warns about deaths in cancer drug trialsAn increased risk of deaths for patients in clinical trials receiving this cancer drug and two other drugs led FDA to stop the clinical trials.
FDA Warning on KeytrudaAfter trials halted, FDA issues warning on off-label use of the drug.
Robust multiple myeloma treatment program holds promiseThe Medical College of Wisconsin’s multiple myeloma program is robust and growing.
Integrating pharmacy benefit, medical benefit cuts costsHere’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.
FDA approves a new immune-stimulating drug to treat multiple myelomaFDA has approved elotuzumab (Empliciti, Bristol-Myers Squibb and AbbVie) for the treatment of multiple myeloma.
FDA approves first immunostimulatory antibody for multiple myelomaAn oncology expert at ASH will present extended follow-up and overall survival data from ELOQUENT-2, the study on which Empliciti is approved.
First-of-its kind myeloma drug approvedThe FDA accelerated approval for Darzalex injection for intravenous infusion for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy or who are double-refractory to a PI and an immunomodulatory agent.
Oncology drugs in the pipelineSeveral new drugs hold promise, but cost is a top concern.